GlassScriptPhysician profile
Darla E Eisenhauer-Spires
NPI 1669420774
$4,003.28
in general payments reported to CMS, 2019-2025
29 companies · $786 in 2025
The $786 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $510 · 2021: $577 · 2022: $98.49 · 2023: $766 · 2024: $756 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,209 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,209.43 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $899.66 | 2019-2025 | |
| Astellas Pharma US INC | $866.18 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $332.45 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $279.01 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $177.59 | 2021-2025 | Slynd |
| Novo Nordisk INC | $151.38 | 2019-2024 | Wegovy |
| Organon LLC | $143.01 | 2021-2025 | Nexplanon, Jada System |
| Daiichi Sankyo INC. | $123.35 | 2019-2024 | Injectafer |
| Coopersurgical, INC. | $102.05 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Mayne Pharma Commercial LLC | $101.32 | 2021-2025 | |
| Biogen, INC. | $99.37 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $92.26 | 2021-2024 | |
| Myriad Women'S Health, INC. | $91.35 | 2023 | Myrisk |
| Merck Sharp & Dohme LLC | $90.90 | 2019-2024 | Gardasil 9, Gardasil |
| Therapeuticsmd, INC. | $87.99 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $63.60 | 2019-2020 | |
| Amgen INC. | $63.45 | 2019-2024 | Evenity, Prolia |
| Hologic Sales and Service, LLC | $58.71 | 2024-2025 | Acessa Provu System, Sonata Sonography-Guided Transcervical Fibroid Ablation System, Novasure |
| Lupin INC. | $25.66 | 2020 | |
| Lilly USA, LLC | $25.52 | 2021 | |
| Myovant Sciences INC. | $20.92 | 2022 | |
| Medtronic, INC. | $18.96 | 2023 | V-Loc 180 |
| Gynesonics, INC. | $17.85 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Boston Scientific Corporation | $13.16 | 2019 | |
| Meditrina | $12.44 | 2021 | |
| Duchesnay USA Incorporated | $11.86 | 2019 | |
| Kci USA, INC. | $11.29 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.14 | 2020 | |
| Covidien LP | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darla Eisenhauer-Spires listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.